A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
Psoriasis
Interventions
DRUG

BMS-986322

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (35)

3044

Local Institution - 0045, Pascoe Vale South

3053

Local Institution - 0019, Carlton

4102

Local Institution - 0024, Brisbane

64064

Local Institution - 0060, Lee's Summit

66211

Local Institution - 0057, Leawood

77598

Local Institution - 0011, Webster

90056

Local Institution - 0016, Los Angeles

91436

Local Institution - 0012, Encino

94538

Local Institution - 0002, Fremont

1738606

Local Institution - 0023, tabashi City

35205-5021

Local Institution - 0006, Birmingham

92708-3701

Local Institution - 0005, Fountain Valley

90045-3606

Local Institution - 0001, Los Angeles

92701-2201

Local Institution - 0003, Santa Ana

33134-5736

Local Institution - 0013, Coral Gables

60077-1049

Local Institution - 0056, Skokie

47129-2201

Local Institution - 0044, Clarksville

01915-1672

Local Institution - 0004, Beverly

03801

Local Institution - 0007, Portsmouth

27713-8507

Local Institution - 0055, Durham

44106-1716

Local Institution - 0008, Cleveland

57702-9208

Local Institution - 0058, Rapid City

75230-5808

Local Institution - 0059, Dallas

A1E 1V4

Local Institution - 0062, St. John's

L4M 7G1

Local Institution - 0034, Barrie

L8L 3C3

Local Institution - 0020, Hamilton

N6A 2C2

Local Institution - 0041, London

M2N 3A6

Local Institution - 0030, Toronto

064-0807

Local Institution - 0049, Sapporo

814-0180

Local Institution - 0051, Fukuoka

173-8610

Local Institution - 0042, Itabashi-Ku

467-8602

Local Institution - 0026, Nagoya

514-8507

Local Institution - 0027, Tsu

LE10 2SE

Local Institution - 0050, Hinckley

E11 1NR

Local Institution - 0046, Leytonstone

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05730725 - A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis | Biotech Hunter | Biotech Hunter